

INSULINS

Preparation	Brand		Route	Onset (hrs)	Peak (hrs)	Duration (hrs)	Source
INJECTABLES							
insulin aspart	Fiasp²	Rx	SC, IV ⁴	0.27–0.33	1.5–2.2	5–7	human
	NovoLog²	Rx	SC, IV ⁴ , CSII	≤0.25	1–3	3–5	human
insulin aspart protamine/ insulin aspart	NovoLog Mix 70/30²	Rx	SC	≤0.25	2.4	24	human
insulin degludec	Tresiba²	Rx	SC	1	9	25	human
insulin detemir	Levemir²	Rx	SC	1	none	24	human
insulin glargine	Basaglar²	Rx	SC	—	none	≥24	human
	Lantus³	Rx	SC	1.1	none	≥24	human
	Toujeo³	Rx	SC	6	—	24–120	human
insulin glulisine	Apidra³	Rx	SC, CSII, IV ⁴	≤0.25	1	2–4	human
insulin lispro	Humalog³	Rx	SC, IV ^{4,5} , CSII ⁵	≤0.25	1	3.5–4.5	human
insulin lispro protamine/ insulin lispro	Humalog Mix 75/25³	Rx	SC	≤0.25	0.5–1.5	24	human
	Humalog Mix 50/50³	Rx	SC	≤0.25	1	16	human
insulin injection regular (R)	Humulin R U-100¹	OTC	SC, IV ⁴	0.5	2–4	6–8	human
	Humulin R U-500¹	Rx	SC	0.5	1.75–4	24	human
	Novolin R²	OTC	SC, IV ⁴	0.5	2.5–5	8	human
insulin isophane suspension (NPH)/regular insulin (R)	Humulin 70/30¹	OTC	SC	0.5	2–12	24	human
	Novolin 70/30²	OTC	SC	0.5	2–12	24	human
insulin isophane suspension (NPH)	Humulin N¹	OTC	SC	1–2	6–12	18–24	human
	Novolin N²	OTC	SC	1.5	4–12	24	human
ORAL INHALATIONS							
Insulin	Afrezza	Rx	oral inh	0.2–0.7	—	2–3	human

NOTES

Key: CSII = continuous subcutaneous insulin infusion

¹Recombinant (using *E. coli*)

²Recombinant (using *S. cerevisiae*)

³Recombinant human insulin analogue (using *E. coli*)

⁴IV to be used in a clinical setting under proper medical supervision

⁵IV and CSII administration for Humalog U-100 only.

Onset for injectable formulations is always for the SC route. All times are approximate. Maximum effect occurs between hours listed in duration column; actual effect may last longer. Injectable insulins listed are available in a concentration of 100Units/mL; Humulin R, in a concentration of 500Units/mL for SC injection only, is available by prescription from Lilly for insulin resistant patients who are hospitalized or under close medical supervision.

Not an inclusive list of medications and/or dosing instructions. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 3/2018)